Key clinical point: Low-dose ipilimumab (1 mg/kg) plus pembrolizumab given immediately after progression on a PD-1 antibody alone demonstrated antitumor activity and tolerability in patients with advanced melanoma, according to an investigator.

Major finding: There were 5 complete responses and 14 partial responses, for a response rate of 27%. The rate of grade 3/4 adverse events was 27%.

Study details: Phase 2 study of 70 patients, 61 of whom were evaluable for response.

Disclosures: The study was funded by an investigator-initiated grant from Merck. Dr. Olson had no disclosures. Some of his coinvestigators reported ties to the company.